Research programme: respiratory disorders therapeutics - InterMune
Latest Information Update: 13 Apr 2010
At a glance
- Originator InterMune
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 13 Apr 2010 Discontinued - Preclinical for Respiratory tract disorders in Italy (unspecified route)
- 28 Jun 2007 Preclinical trials in Respiratory tract disorders in Italy (unspecified route)